ライフサイエンスコーパス: fluoromisonidazole

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 lead hypoxia tracers, (64)Cu-ATSM and (18)F-fluoromisonidazole.

2 luation of tumor hypoxia with agents such as fluoromisonidazole.

3 ed with other hypoxia tracers, such as (18)F-fluoromisonidazole.

4 with PET/MRI using the hypoxia tracers (18)F-fluoromisonidazole ((18)F-FMISO) and (18)F-fluoroazomyci

5 ng of tumor hypoxia and perfusion with (18)F-fluoromisonidazole ((18)F-FMISO) dynamic PET (dPET) in h

6 ed pharmacokinetic analysis of (18)F-labeled fluoromisonidazole ((18)F-FMISO) dynamic PET to assist t

7 (18)F-fluoromisonidazole ((18)F-FMISO) is the most widely used

8 ty-three GBM patients were assessed by (18)F-fluoromisonidazole ((18)F-FMISO) PET and conventional an

9 (18)F-fluoromisonidazole ((18)F-FMISO) PET is a noninvasive, q

10 mor perfusion and hypoxia with dynamic (18)F-fluoromisonidazole ((18)F-FMISO) PET may allow for an im

11 -fluoro-2-deoxy-d-glucose ((18)F-FDG), (18)F-fluoromisonidazole ((18)F-FMISO), and 3'-deoxy-3'-(18)F-

12 ctivity of 4 hypoxia PET radiotracers ((18)F-fluoromisonidazole [(18)F-FMISO], (18)F-flortanidazole [

13 ng the uptake of 3 tracers ((18)F-FDG, (18)F-fluoromisonidazole [(18)F-FMISO], and (18)F-fluoride) in

14 Fluorine 18-labeled fluoromisonidazole ([18F]FMISO), a PET tracer that under

15 -bis(N(4)-methylthiosemicarbazone) and (18)F-fluoromisonidazole; amino acids for PET imaging, includi

16 ody molds, injected intravenously with (18)F-fluoromisonidazole, and imaged dynamically for 105 min.

17 N4-methylthiosemicarbazone) (ATSM) and (18)F-fluoromisonidazole are trapped only at extreme levels of

18 ne whether kinetic analysis of dynamic (18)F-fluoromisonidazole data provides better discrimination o

19 Using single-session 45-min shortened (18)F-fluoromisonidazole dPET datasets appears to be adequate

20 editing the clinical implementation of (18)F-fluoromisonidazole dPET protocols.

21 scan, each patient underwent a 45-min (18)F-fluoromisonidazole dPET scan, followed by 10-min acquisi

22 Ninety-minute (18)F-fluoromisonidazole dPET scans were acquired in animals.

23 g using shortened acquisition times in (18)F-fluoromisonidazole dPET, with the goal of expediting the

24 (18)F-fluoromisonidazole dynamic PET (dPET) is used to identif

25 d the biodistributions of [18F]FETA and [18F]fluoromisonidazole (FMISO) at 2 and 4 h postinjection in

26 -thymidine for cellular proliferation, (18)F-fluoromisonidazole (FMISO) for tissue hypoxia, and (11)C

27 Fluoromisonidazole (FMISO), labeled with the positron em

28 th GBM were imaged preoperatively with (18)F-fluoromisonidazole (FMISO)-PET and serial gadolinium-enh

29 Bq bolus of each candidate tracer (and (18)F-fluoromisonidazole for comparative purposes) was injecte

30 Cardiac retention of (18)F-fluoromisonidazole increased from 0.44% +/- 0.17% during

31 bazone) (Cu-PTSM) and the hypoxic tracer 18F-fluoromisonidazole (MISO).

32 ighted MRI (T2), and hypoxia assessed by 18F-fluoromisonidazole PET (18F-FMISO).

33 (18)F-fluoromisonidazole PET, a noninvasive means of identifyi

34 Animals underwent (18)F-fluoromisonidazole positron emission tomographic and (18

35 (18)F-fluoromisonidazole positron emission tomographic imaging

36 F-labelled fluoromisonidazole positron emission tomography imaging

37 Furthermore, the (18)F-fluoromisonidazole signal was high at the early stages.

38 (18)F-fallypride and (18)F-fluoromisonidazole, two well-established PET radioligand

39 n tomographic imaging corroborated the (18)F-fluoromisonidazole uptake by the aorta of atheroscleroti

40 The dynamic (18)F-fluoromisonidazole uptake data were fitted with 2 varian

41 were assessed by immunohistochemistry.(18)F-fluoromisonidazole uptake increased with time on diet (s

42 (18)F-fallypride and (18)F-fluoromisonidazole were successfully synthesized.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。